Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphoid neoplasia.

Umbralisib Demonstrates Safety, Efficacy for Patients With Kinase Inhibitor–Intolerant CLL

According to a report presented at the 23rd Congress of the European Hematology Association, the phosphoinositide 3-kinase (PI3K) and casein kinase-1ε inhibitor umbralisib represents...

Is Chronic Lymphocytic Leukemia Curable With Newer Agents?

Chronic lymphocytic leukemia (CLL) has long been considered an incurable disease. The goal of traditional frontline treatments is to minimize disease burden and allow...

Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL

The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...

Extended Analysis Shows Venetoclax Continues to Produce Deep Responses in CLL

In 2016, the U.S. Food and Drug Administration granted venetoclax accelerated approval for the treatment of adults with previously treated chronic lymphocytic leukemia (CLL)...

Combining Ibrutinib and Venetoclax Produces High MRD-Negative Rates in Treatment-Naïve CLL

The all-oral regimen of single-agent ibrutinib followed by combined ibrutinib and venetoclax increased the odds that patients with treatment-naïve chronic lymphocytic leukemia (CLL) will...

Updated Results from JULIET: Tisagenlecleucel Associated With Durable Responses in DLBCL

In May 2018, the U.S. Food and Drug Administration expanded the approval of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel to the treatment...

FDA Approves Pembrolizumab for Relapsed/Refractory PMBCL

Pembrolizumab was granted an accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with refractory...

Obinutuzumab Beats Rituximab in Older Patients With CLL

Treatment with obinutuzumab plus chlorambucil led to greater improvements in progression-free survival (PFS) and overall survival (OS) than the combination of rituximab and chlorambucil,...

Lenalidomide Therapy Increases VTE Risk in B-Cell Non-Hodgkin Lymphoma

Patients with B-cell non-Hodgkin lymphoma (NHL) treated with lenalidomide have an increased risk of developing venous thromboembolism (VTE) – similar to the increased risk...
WIB_icon

Treating MPNs With JAK1/2 Inhibitors Increases Risks for B-Cell Lymphomas

JAK1/2 inhibitors have been used as standard and experimental treatment of myeloproliferative neoplasms (MPNs) for years, but according to research published in Blood, their...

SHARE